Observations and Commentary on Medicine and Current Events
This is part 2 of an article where was interviewed for at Bio Similar Development. The article was discussing biosimilars and their impact on patients, oncologists, and healthcare system. This is critical as we are experiencing changes in reimbursement models and operational challenges for effective healthcare delivery.
As we kicked off 2020, one of the most anticipated events for the industry was the introduction of several more Herceptin, Avastin, and Rituxan competitors in the curative oncology mAb space. After the first three launches which will be completed in March, the U.S. will have finally welcomed a little more than half of the 26 biosimilars currently approved.
I read this fascinating book “Chasing my Cure” written by the amazing David Fajgenbaum on his journey fighting Castleman Disease. Battling this disease has shaped David’s journey and forming the Castleman Disease Collaborative Network (CDCN). I then interviewed David on my “Outspoken Oncology” Podcast.
Mark Lewis and I reflected on ASCO-19 and how all stakeholders were involved. It was truly fun to write this piece for the ASCO-Post.
Interviewing Dr. DeVita was a dream coming true; I interviewed him for my podcast and wrote a book review for the HealthCareBlog on his “The Death of Cancer” book. Dr. DeVita is a pioneer of lymphoma and is an icon for every oncologist, so having him on my podcast was an honor I will never forget.
This is a republication of an article I originally wrote for the HealthCareBlog. Life is busy, yet we somehow find time to stay engaged on social media, remain engrossed in the 24/7 news cycle, and continue our futile efforts to resist clickbait. While social media can allow us to mindlessly scroll through feeds, it also provides … Read more
This opinion article was originally published at STAT news. As precision medicine opens up promising new advances in cancer care, I often think back to my early days as an oncologist, the patients I treated, and the limited treatment options I had for them. I especially remember Pam (not her real name). She was in her early … Read more